Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib + durvalumab in Chinese patients with EGFR wild-type, MET-aberrant advanced or metastatic NSCLC
CTR20221360Phase 2Suspended
- Sponsor
- MedImmune
- Start
- Nov 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib, durvalumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Nov 2022; status: suspended.
02
Drugs
savolitinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221360.